1207 related articles for article (PubMed ID: 11371126)
21. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3.
Abdollahi T; Robertson NM; Abdollahi A; Litwack G
Cancer Res; 2003 Aug; 63(15):4521-6. PubMed ID: 12907626
[TBL] [Abstract][Full Text] [Related]
22. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
[TBL] [Abstract][Full Text] [Related]
23. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
24. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines.
Kim DM; Koo SY; Jeon K; Kim MH; Lee J; Hong CY; Jeong S
Cancer Res; 2003 Feb; 63(3):621-6. PubMed ID: 12566305
[TBL] [Abstract][Full Text] [Related]
25. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S
Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756
[TBL] [Abstract][Full Text] [Related]
26. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
Fan QL; Zou WY; Song LH; Wei W
Cancer Chemother Pharmacol; 2005 Feb; 55(2):189-96. PubMed ID: 15290100
[TBL] [Abstract][Full Text] [Related]
27. Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection.
Clarke P; Meintzer SM; Spalding AC; Johnson GL; Tyler KL
Oncogene; 2001 Oct; 20(47):6910-9. PubMed ID: 11687970
[TBL] [Abstract][Full Text] [Related]
28. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells.
Shi RX; Ong CN; Shen HM
Cancer Res; 2005 Sep; 65(17):7815-23. PubMed ID: 16140950
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
30. C-jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines.
Mikami T; Koyama T; Koyama T; Imakiire A; Yamamoto K; Furuhata M; Toyota H; Mizuguchi J
Anticancer Res; 2006; 26(2A):1153-60. PubMed ID: 16619517
[TBL] [Abstract][Full Text] [Related]
31. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
32. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
33. Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB.
Yang X; Merchant MS; Romero ME; Tsokos M; Wexler LH; Kontny U; Mackall CL; Thiele CJ
Cancer Res; 2003 Mar; 63(5):1122-9. PubMed ID: 12615731
[TBL] [Abstract][Full Text] [Related]
34. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
35. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis.
Hernandez A; Thomas R; Smith F; Sandberg J; Kim S; Chung DH; Evers BM
Surgery; 2001 Aug; 130(2):265-72. PubMed ID: 11490359
[TBL] [Abstract][Full Text] [Related]
36. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
Nagane M; Pan G; Weddle JJ; Dixit VM; Cavenee WK; Huang HJ
Cancer Res; 2000 Feb; 60(4):847-53. PubMed ID: 10706092
[TBL] [Abstract][Full Text] [Related]
37. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD
Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919
[TBL] [Abstract][Full Text] [Related]
38. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.
Petrucci E; Pasquini L; Petronelli A; Saulle E; Mariani G; Riccioni R; Biffoni M; Ferretti G; Benedetti-Panici P; Cognetti F; Scambia G; Humphreys R; Peschle C; Testa U
Gynecol Oncol; 2007 May; 105(2):481-92. PubMed ID: 17292950
[TBL] [Abstract][Full Text] [Related]
39. Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy.
Odoux C; Albers A
Vitam Horm; 2004; 67():385-407. PubMed ID: 15110187
[TBL] [Abstract][Full Text] [Related]
40. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
Thai le M; Labrinidis A; Hay S; Liapis V; Bouralexis S; Welldon K; Coventry BJ; Findlay DM; Evdokiou A
Cancer Res; 2006 May; 66(10):5363-70. PubMed ID: 16707463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
